^
Association details:
| Biomarker: | EGFRvIII mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
Excerpt:
Additionally, we found that the EGFRvIII mutant, which does not have a mutation in the kinase domain, was also more sensitive to gefitinib than wild type EGFR in transfected cells (Figures 1 and 2).
DOI:
10.1038/sj.onc.1209159
